Parkinson’s Disease -Drug Pipeline Analysis and Market Forecasts to 2015

ChinaCCM Logo

Parkinson’s Disease -Drug Pipeline Analysis and Market Forecasts to 2015

GlobalData, the industry analysis specialist’s new report, “Parkinson’s Disease-Drug Pipeline Analysis and Market Forecasts to 2015” is an essential source of information and analysis on the global Parkinson’s disease market. The report identifies…
PR Log (Press Release)May 06, 2010 – Summary
The scope of the report includes:

-Annualized global Parkinson’s disease market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
-Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes dopamine agonists, adenosine receptor antagonists, serotonin receptor targetters, glutamate receptor antagonists, NMDA receptor targetters, AMPA receptor antagonists, stem cell and gene therapy.
-Analysis of the current and future market competition in the global Parkinson’s disease market. Key future market players covered are Merck Serono, Acadia Pharmaceuticals, Axxonis Pharma AG, Avicena Group Inc., and Solvay Pharmaceuticals.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with Parkinson’s disease.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global Parkinson’s disease market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global Parkinson’s disease market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective   counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What’s the next big thing in the global Parkinson’s disease market landscape?-Identify, understand and capitalize.

Table of Contents
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Parkinson’s Disease Market: Market Characterization 6
2.1 Overview 6
2.2 Parkinson’s Disease Market Size 6
2.3 Parkinson’s Disease Market Forecast and CAGR 6
2.4 Drivers and Barriers for the Parkinson’s Disease Market 7
2.4.1 Drivers for the Parkinson’s Disease Market 7
2.4.2 Barriers for the Parkinson’s Disease Market 7
2.5 Opportunity and Unmet Need 7
2.6 Key Takeaway 9
3 Parkinson’s Disease Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Profile for the Major Marketed Products in the PD Market 11
3.3.1 Stalevo (levodopa, carbidopa, entacapone) 11
3.3.2 Requip XL (ropinirole XL) 12
3.3.3 Azilect (rasagiline mesylate) 13
3.3.4 Mirapex/Sifrol/Mirapexin (pramipexole dihydrochloride) 14
3.4 Other Marketed Products for the Parkinson’s Disease Market 15
3.4.1 Comtan (entacapone) 15
3.4.2 Tasmar (tolcapone) 15
3.5 Key Takeaway 16
4 Parkinson’s Disease Market: Pipeline Assessment 18
4.1 Overview 18
4.2 Strategic Pipeline Assessment 18
4.2.1 Technology Trends Analytic Framework 18
4.3 Parkinson’s Disease Therapeutics-Promising Drugs under Clinical Development 20
4.4 Molecule Profile for Promising Drugs under Clinical Development 21
4.4.1 Safinamide 21
4.4.2 Pimavanserin 21
4.4.3 PD-02 22
4.4.4 SLV 308 (pardoprunox) 23
4.4.5 Lisuride (patch and subcutaneous (sc) infusion) 23
4.5 Parkinson’s Disease Therapeutics Market-Clinical Pipeline by Mechanism of Action 24
4.6 Parkinson’s Disease Pipeline-Pipeline by Clinical Phases of Development 25
4.6.1 Parkinson’s Disease Therapeutics-Phase III Clinical Pipeline 25
4.6.2 Parkinson’s Disease Therapeutics-Phase II Clinical Pipeline 26
4.6.3 Parkinson’s Disease Therapeutics-Phase I Clinical Pipeline 27
4.6.4 Parkinson’s Disease Therapeutics-Preclinical Pipeline 28
4.6.5 Parkinson’s Disease Therapeutics-Discovery Pipeline 29
4.7 Discontinued/Suspended Drugs for Parkinson’s Disease 30
4.8 Key Takeaway 32
5 Parkinson’s Disease Market: Implications for Future Market Competition 33
6 Parkinson’s Disease Market: Future Players in the Parkinson’s Disease Market 35
6.1 Introduction 35
6.2 Merck Serono 35
6.2.1 Overview 35
6.2.2 CNS Portfolio 35
6.2.3 Parkinson’s Disease Product Portfolio 36
6.3 Acadia Pharmaceuticals 37
6.3.1 Overview 37
6.3.2 CNS Portfolio 37
6.3.3 Parkinson’s Disease Product Portfolio 37
6.4 Axxonis Pharma AG 38
6.4.1 Overview 38
6.4.2 CNS Portfolio 38
6.4.3 Parkinson’s Disease Product Portfolio 38
6.5 Avicena Group Inc. 39
6.5.1 Overview 39
6.5.2 CNS Portfolio 39
6.5.3 Parkinson’s Disease Product Portfolio 39
6.6 Solvay Pharmaceuticals 40
6.6.1 Overview 40
6.6.2 CNS Portfolio 40
6.6.3 Parkinson’s Disease Product Portfolio 41
7 Parkinson’s Disease Market: Appendix 42
7.1 Market Definitions 42
7.2 Abbreviations 42
7.3 Research Methodology 43
7.3.1 Coverage 44
7.3.2 Secondary Research 44
7.3.3 Forecasting 44
7.3.4 Primary Research 46
7.3.5 Expert Panel Validation 47
7.4 Contact Us 47
7.5 Disclaimer 47
7.6 Sources 47

List of Tables
1.1 List of Tables
Table 1: Global Parkinson’s Disease Therapeutics Market, Revenue Forecasts, 2000-2008 7
Table 2: Global Parkinson’s Disease Therapeutics Market, Revenue Forecasts, 2009-2015 7
Table 3: Major Marketed Products Comparison in the Parkinson’s Disease Market, 2009 17
Table 4: Parkinson’s Disease Therapeutics-Most Promising Drugs under Clinical Development, 2009 20
Table 5: Parkinson’s Disease Therapeutics-Phase III Clinical Pipeline, 2009 25
Table 6: Parkinson’s Disease Therapeutics-Phase II Clinical Pipeline, 2009 26
Table 7: Parkinson’s Disease Therapeutics-Phase I Clinical Pipeline, 2009 27
Table 8: Parkinson’s Disease Therapeutics-Preclinical Pipeline, 2009 28
Table 9: Parkinson’s Disease Therapeutics-Discovery Pipeline, 2009 29
Table 10: List of Discontinued Drugs for Parkinson’s Disease, 2009 30
Table 11: Merck Serono-CNS Marketed Products, 2009 35
Table 12: Merck Serono-CNS Pipeline Products, 2009 36
Table 13: Acadia Pharmaceuticals-CNS Pipeline Products, 2009 37
Table 14: Axxonis Pharma AG-CNS Pipeline Products, 2009 38
Table 15: Avicena Group Inc.-CNS Pipeline Products, 2009 39
Table 16: Solvay Pharmaceuticals-CNS Marketed Products, 2009 40
Table 17: Solvay Pharmaceuticals-CNS Pipeline Products, 2009 41

Reblog this post [with Zemanta]


  This content has been Digiproved

Advertisements
This entry was posted in Healthcare. Bookmark the permalink.

One Response to Parkinson’s Disease -Drug Pipeline Analysis and Market Forecasts to 2015

  1. Pingback: Huntington Disease Therapy Area Pipeline Report | Common Diseases | Your Personal Health Care Blog

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s